Articles tagged "Graft acceptance"

2016 American Transplant Congress
Treg-Rich Organized Lymphoid Structures (TOLS) in Spontaneously Accepted Mouse Kidney Allografts.
C. Yang,¹ E. Farkash,² D. Ndishabandi,¹ R. White,¹ B. Jiang,¹ I. Aljabban,¹ P. Russell,¹ J. Madsen,¹ R. Colvin,¹ A. Alessandrini.¹
¹Center for Transplantation Sciences, Dept. of Surgery, Dept. of Pathology, Massachusetts General Hospital, Boston, MA; ²University of Michigan School of Medicine, Ann Arbor, MI.
Background: In many MHC mismatched strain combinations (e.g., DBA/2 to B6) kidney allografts are spontaneously accepted without immunosuppression. This tolerance is regulatory, initially dependent Foxp3+…
2016 American Transplant Congress
Urinary Expression of miRNA-155, miRNA-210, miRNA-142 and CXCL-10 Production Predicts the Risk of Acute Rejection and Graft Outcome in Renal Transplant Recipients.
O. Millan,¹ K. Budde,² C. Sommerer,³ I. Aliart,¹ O. Rissling,² B. Bardaji,⁴ M. Matz,² M. Zeier,³ I. Silva,⁴ L. Guirado,⁴ M. Brunet.¹
¹Pharmacology Laboratory, CDB, IDIBAPS, Hospital Clinic Barcelona, Barcelona University, Barcelona, Spain; ²Medizinische Klinik mit Schwerpunkt Nephrologie, Charité Universitätsmedizin, Berlin, Germany; ³Department of Nephrology, University Hospital Heidelberg and Mannheim, Heidelberg, Germany; ⁴Renal Transplant Unit, Fundació Puigvert, Barcelona, Spain.
MicroRNAs (miRs) have been reported to play a role in immune system response. The results of several clinical trials have suggested that these molecules might…
2016 American Transplant Congress
Rapamycin (RPM) Synergizes with CD154 mAb and DST to Promote Long-Term Vascularized Composite Allograft (VCA) Survival, but Prevents Induction of Donor-Specific Tolerance.
L. Wang, Z. Wang, R. Han, T. Bhatti, L. Levin, M. Levine, W. Hancock.
CHOP & UPenn, Philadelphia.
Even though CD154 mAb (MR-1) plus donor splenocyte transfusion (DST) is very effective at inducing tolerance of various allografts, such as those of hearts, kidneys…
2016 American Transplant Congress
Understanding the Initial Rise in Kidney Discard Rates Observed Post-KAS.
D. Stewart,¹ A. Kucheryavaya,¹ R. Brown,¹ D. Klassen,¹ N. Turgeon,² M. Aeder.³
¹UNOS, Richmond, VA; ²Emory Univ, Atlanta, GA; ³Univ Hosp Case Med Ctr, Cleveland, OH.
Background: Kidney discard rates increased by 10% -- from 18.3% to 20.2% (p=0.001) -- during the first 7 months of KAS but returned to pre-KAS…
2016 American Transplant Congress
Tolerogenic Interactions Between Host CD8⁺Myeloid Dendritic Cells and Natural Killer T Cells Are Required for Acceptance of Combined Organ and Bone Marrow Transplants After TLI Conditioning.
D. Hongo Apum,¹ X. Zhang,² E. Engleman,² S. Strober.¹
¹Medicine - Division of Immunology & Rheumatology, Stanford University, Stanford, CA; ²Medicine - Department of Pathology, Stanford University, Stanford, CA.
Combined transplantation of solid organs and bone marrow or hematopoietic progenitor cells has resulted in successful achievement of tolerance in both laboratory animals and in…
2016 American Transplant Congress
Distinct Phenotype and Function of Plasmacytoid Dendritic Cells from Kidney Allografts in Tolerant Recipients.
N. Oh,^1,2 C. Yang,^1,2,3 M. Tonsho,^1,2 D. Ndishabandi,^1,2,3 P. Russell,^1,2 R. Colvin,^1,3 J. Madsen,^1,2 A. Alessandrini.^1,2
¹Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA; ²Department of Surgery, Massachusetts General Hospital, Boston, MA; ³Department of Pathology, Massachusetts General Hospital, Boston, MA.
BACKGROUND: Cellular infiltrates in kidney allografts may be relevant to the induction or maintenance of regulatory tolerance. Here we examined the phenotype, anatomical distribution and…
2016 American Transplant Congress
Everolimus in Combination with Reduced Dose Tacrolimus Is Effective as a Prophylaxis of Acute Rejection in Low-to-Moderate Immunologic Risk De Novo Kidney Transplantation Patients.
Y. Qazi, F. Shihab, S. Mulgaonkar, K. MaCague, D. Patel.
University of Southern California, Los Angeles; University of Utah, Salt Lake City; Barnabas Health, West Orange; Novartis Pharmaceuticals Corporation, East Hanover.
The US92 study determined whether, in de novo renal transplant patients (pts), concentration-controlled everolimus (EVR) with reduced dose tacrolimus (RTAC) is non-inferior compared to CellCept®…
2016 American Transplant Congress
Targeting IFN-g-Expressing TIM-4⁺B Effector (Beff) Cells as a Novel Strategy to Prevent Allograft Rejection.
Q. Ding,¹ K. Mohib,¹ S. Xiao,² V. Kuchroo,² D. Rothstein.¹
¹University of Pittsburgh, Pittsburgh; ²Harvard Medical School, Boston.
B cell depletion can augment or inhibit auto- and allo- immune responses in humans and mice without altering Ig levels. This is likely due to…
2015 American Transplant Congress
Structure/Function Insights Into Treg Biology: Hdac11 Is a Foxp3 Deacetylase Whose Targeting Promotes and Stabilizes Foxp3 Expression and Leads to Long-Term Allograft Survival
J. Huang,¹ L. Wang,¹ T. Bhatti,¹ A. Samanta,¹ S. Dahiya,¹ R. Han,¹ J. Bergman,² A. Kozikowski,² W. Hancock.¹
¹CHOP & UPenn, Philadelphia; ²Uni of Illinois at Chicago, Chicago.
Aim: There are huge scientific, economic and practical advantages in developing pharmacologic approaches to enhance Foxp3+ Treg function in allograft recipients versus simply injecting enormous…
2015 American Transplant Congress
IL-21 Regulates Creation of Tertiary Lymphoid Organs in Chronic Allograft Rejection
C. Baum,¹ M. Khattar,² P. Schroder,¹ W. Chen,³ S. Stepkowski.¹
¹Medical Microbiology and Immunology, University of Toledo College of Medicine, Toledo, OH; ²Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, MA; ³Transplant Immunology Research Program, Houston Methodist Research Institute, Houston, TX.
BACKGROUND: IL-21 is a cytokine expressed almost exclusively by cells of the adaptive immune system. This makes it an attractive target for reducing chronic allograft…